# Progress Note 07 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Howard Hughes (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML006-SYN
- Date: 2026-10-05
- Fictional facility: St. Posthumous Health Center
- Fictional author: Anselm Garrity-Moyo, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Twenty-two-week review: OCD response, buprenorphine, pain, weight and laboratory checks. **S**

## History of present illness

Mr. Hughes returns three weeks after his preventive visit and twelve weeks after the increase to sertraline 200 mg, which he tolerates with mild night sweats; the nurse call two weeks after the increase found no problems. He has had twenty exposure sessions. He eats in a restaurant once a week, holds meetings without asking visitors about illness, and no longer needs sealed milk bottles. Washing and checking take about one hour a day, and he says the fears are now "background noise." He has used no opioid other than buprenorphine; the urine test today was positive for buprenorphine and negative for other opioids and fentanyl. He wears his hearing aids every day and uses the remote microphone in meetings. He would like his COVID-19 vaccine today. **S**

| Element | Detail |
|---|---|
| Rituals | About one hour a day; Y-BOCS 14 |
| Sertraline | 200 mg for twelve weeks; mild night sweats |
| Buprenorphine | 8 mg twice daily; urine test as expected |
| Pain | PEG 4.0 |
| Weight | 76.2 kg, up 4.2 kg since intake |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good; weight up |
| Gastrointestinal | Negative | Bowels regular |
| Musculoskeletal | Positive | Mild chest wall and back pain on long days |
| Psychiatric | Negative | Contamination fears mild; mood good; no thoughts of suicide or of harming anyone |

4 systems reviewed. **S**

## Current medications

- Naloxone 4 mg nasal spray, one spray into one nostril for a suspected opioid overdose, repeated every two to three minutes in the other nostril if needed; two-pack dispensed, with instruction for him and his household staff **S**
- Buprenorphine 8 mg with naloxone 2 mg sublingual film, one film twice daily (16 mg a day), for opioid use disorder and pain; dispensed one week at a time at first **S**
- Acetaminophen 500 mg oral tablet, two tablets three times daily (3,000 mg a day) for pain after the crash, now that codeine combination tablets have stopped **S**
- Sertraline 100 mg oral tablet, two tablets daily (200 mg), the usual target range for OCD **S**

## Allergies

- No known allergy **S**

## Objective

BP 118/76 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 76.2 kg; BMI 20.9 kg/m². All vital signs are synthetic.

Sodium: 140 mmol/L; Potassium: 4.3 mmol/L; Creatinine: 0.96 mg/dL; eGFR (CKD-EPI 2021): 102 mL/min/1.73 m²; Glucose: 86 mg/dL; AST: 24 U/L; ALT: 27 U/L; Albumin: 4.2 g/dL; PHQ-9: 4; GAD-7: 6; PEG pain scale: 4. All results are synthetic.

## Change since baseline

- Sodium: 139 mmol/L at baseline, 140 mmol/L at this visit **S**
- Potassium: 4.2 mmol/L at baseline, 4.3 mmol/L at this visit **S**
- Creatinine: 0.94 mg/dL at baseline, 0.96 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 104 mL/min/1.73 m² at baseline, 102 mL/min/1.73 m² at this visit **S**
- Glucose: 84 mg/dL at baseline, 86 mg/dL at this visit **S**
- AST: 31 U/L at baseline, 24 U/L at this visit **S**
- ALT: 38 U/L at baseline, 27 U/L at this visit **S**
- Albumin: 3.7 g/dL at baseline, 4.2 g/dL at this visit **S**
- PHQ-9: 9 at baseline, 4 at this visit **S**
- GAD-7: 12 at baseline, 6 at this visit **S**
- PEG pain scale: 6.7 at baseline, 4 at this visit **S**

## Immunizations given today

- COVID-19 vaccine for the coming season **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 118/76, pulse 72; weight 76.2 kg, BMI 20.9 |
| Skin | Hands healed |
| Musculoskeletal | Full left shoulder elevation; mild tenderness of the left lower ribs |
| Psychiatric | Relaxed and humorous; insight good |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Obsessive-compulsive disorder, responding** (F42.2). Y-BOCS 14, a 50 percent fall from 28: a full response, so augmentation is not needed. Sodium 140 mmol/L on sertraline 200 mg. Safety reviewed: no thoughts of suicide or of harming anyone. **S**
   - Continue sertraline 200 mg for at least a year after response.
   - Exposure and response prevention weekly, then booster sessions, with relapse prevention.
2. **Opioid use disorder on buprenorphine** (F11.20). Five months on buprenorphine without other opioid use. Treatment continues without a set end date; any taper later will be his decision. **S**
   - Continue buprenorphine; dispensed four weeks at a time; naloxone at home.
3. **Chronic pain after major trauma** (G89.21). PEG 4.0, at his goal; working full days. **S**
   - Home exercise program; physical therapy as needed.
4. **Weight loss, recovering** (R63.4). 76.2 kg, at his goal; albumin 4.2 g/dL. Kidney function and liver enzymes normal on scheduled acetaminophen. **S**
   - Weight at each visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | OCD severity (Y-BOCS, clinician-rated) and time spent on rituals | Every visit | Completed today | Y-BOCS 14, a 50 percent fall; about one hour a day |
| Referral | Exposure and response prevention: sessions attended and home practice | Weekly, then twice weekly | Completed today | Twenty sessions attended; moving to weekly, then booster sessions |
| Medication safety | SSRI tolerability and adherence: side effects, sodium, bleeding risk, activation or new suicidal thoughts | Every visit, and two weeks after each start or dose change | Completed today | Nurse call after the increase done; mild night sweats; sodium 140 mmol/L |
| Self-management | Accommodation by staff, reduced step by step with his consent | Every visit | Completed today | No rituals carried out by staff apart from his own choice of sealed water bottles at the factory |
| Survey | Depression (PHQ-9) and anxiety (GAD-7) | At baseline and at least monthly during acute treatment | Completed today | PHQ-9 4, item 9 scored 0; GAD-7 6 |
| Survey | Suicide risk review, safety plan and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or of harming anyone; 988 in his phone |
| Self-management | Opioid use and cravings (his own account), buprenorphine adherence and side effects (sedation, constipation) | Every visit | Completed today | No cravings and no other opioid use |
| Laboratory | Urine drug test with fentanyl and buprenorphine, with consent | At start, then about monthly in the first months | Completed today | Positive for buprenorphine, negative for fentanyl and other opioids |
| Medication safety | Prescription drug monitoring program check | Before every controlled-substance prescription | Completed today | Only this clinic's buprenorphine |
| Medication safety | Naloxone at home and household staff trained | Every visit | Completed today | Naloxone at home |
| Survey | Pain intensity and interference (PEG) and function | Every visit | Completed today | PEG 4.0 |
| Examination | Weight, meals and nutrition | Every visit | Completed today | 76.2 kg, BMI 20.9; albumin 4.2 g/dL |
| Laboratory | Kidney function, liver enzymes and albumin | At baseline and at about six months on scheduled acetaminophen | Completed today | Potassium 4.3 mmol/L, creatinine 0.96 mg/dL, eGFR 102, glucose 86 mg/dL, AST 24, ALT 27 |
| Imaging | Hearing: audiometry, hearing aids and use | Audiometry once; hearing aid review after fitting | Completed today | Audiologist review last month; hearing aids worn daily |

## Goal progress

- Y-BOCS down by at least 35 percent (response) within six months. Outcome by 2026-10-05: Y-BOCS 28 at intake, 14 at twenty-two weeks (a 50 percent fall); washing and checking about one hour a day. **S**
- Stop codeine and stay on buprenorphine with no use of other opioids. Outcome by 2026-10-05: Codeine stopped at one week; all urine tests positive for buprenorphine and negative for other opioids. **S**
- Pain that lets him work and sleep: PEG at or below 4. Outcome by 2026-10-05: PEG 6.7 at intake to 4.0 at twenty-two weeks. **S**
- Regain weight to at least 76 kg with regular meals. Outcome by 2026-10-05: 72.0 kg at intake to 76.2 kg; three meals a day, including food prepared by his cook. **S**
- Follow conversation in meetings with hearing aids. Outcome by 2026-10-05: Hearing aids fitted at ten weeks and worn every day. **S**
- Staff stop carrying out rituals for him, step by step, by his own plan. Outcome by 2026-10-05: Tissue-wrapping and the hand-washing rule for staff stopped; food preparation rules relaxed; visitors no longer screened for illness. **S**

## Guideline basis

- Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder (2007), American Psychiatric Association (American Journal of Psychiatry 2007;164(7 Suppl):5-53)
- Guideline Watch (March 2013): Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder (Koran LM, Simpson HB), as reported by Psychiatric News (2013), American Psychiatric Association
- Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31) (2005), National Institute for Health and Care Excellence
- CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022 (2022), Centers for Disease Control and Prevention (MMWR Recommendations and Reports 2022;71(3):1-95)
- The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020), American Society of Addiction Medicine (Journal of Addiction Medicine)
- Prescription Drug Monitoring Programs (PDMPs) (2026), Centers for Disease Control and Prevention
- Hearing loss in adults: assessment and management (NG98) (2018), National Institute for Health and Care Excellence
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- COVID-19 vaccine given today. Second hepatitis B dose next week. Review in three months. Call the clinic or 988 at any time. **S**

